Gurusinghe A D, Land S A, Birch C, McGavin C, Hooker D J, Tachedjian G, Doherty R, Deacon N J
AIDS Molecular Biology Laboratory, Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia.
J Med Virol. 1995 Jul;46(3):238-43. doi: 10.1002/jmv.1890460312.
Sequential human immunodeficiency virus type 1 (HIV-1) isolates were obtained over a 29-month period from a person before, during, and after AZT therapy. DNA sequence analysis of polymerase chain-amplified reverse-transcriptase gene showed a gradual accumulation of mutations to peak resistance (IC50 2.13 microM AZT) in association with mutations at codons 44, 210, and 369, as well as at 41, 67, 70, and 215. Eight months after cessation of AZT therapy, when an HIV-1 isolate from the patient was again sensitive to AZT, these mutations had all returned to the pretherapy sequence.
在29个月的时间里，从一名接受齐多夫定（AZT）治疗前、治疗期间及治疗后的患者身上获取了一系列1型人类免疫缺陷病毒（HIV-1）分离株。对聚合酶链反应扩增的逆转录酶基因进行DNA序列分析显示，与第44、210和369位密码子以及第41、67、70和215位密码子的突变相关，突变逐渐积累至耐药峰值（IC50为2.13 microM AZT）。在停止AZT治疗8个月后，当从该患者身上分离的HIV-1毒株再次对AZT敏感时，这些突变均恢复到治疗前的序列。
